HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment
Breast Cancer Update
00:00
When should endocrine therapy be continued versus switching to chemo or ADCs in HR+ disease?
Dr Huppert favors maximizing endocrine lines when effective and switching sooner for symptomatic or aggressive visceral progression.
Play episode from 27:06
Transcript
